We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed with EUA application to the FDA in...
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...
Β Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation Β TORONTO, February 15, 2022 -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 701 subjects dosed to date Initiating enrollment activities in Turkey as part of its...
Β Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19Β Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...
Β Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantΒ TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive...
TORONTO, Sept. 21, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life...
There are a few different events that can take place that naturally create buying pressure for a stock. One initial catalyst is when a stock is included in an ETF. By nature, the To read the full...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Phase 3 clinical trial ongoing with next DSMB meeting at 600 completed...
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics TORONTO, June 17, 2021 -- InvestorsHub NewsWire...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions